| 英文别名 |
N-(5-(4-(3,3-Dimethylazetidine-1-carbonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide;Solcitinib;GLPG 0778;GLPG-0778;GSK2586184;GSK-2586184;G 154578;GSK 2586184A;GLPG0778;GSK2586184A;GSK 2586184;3V7GQ1260K;AK171373;G154578;N-[5-[4-(3,3-dimethylazetidine-1-carbonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide;Solcitinib [USAN:INN];Solicitinib;N-{5-[4-(3,3-dimethylazetidine-1-carbonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl}cyclopropanecarboxa;HY-16755;compound 1 [WO2010149771];SOLCITINIB [INN];AC-30938;GSK-2586184A;SolcitinibGLPG0778?;MPYACSQFXVMWNO-UHFFFAOYSA-N;DB-109829;SolcitinibGLPG0778;cyclopropanecarboxylic acid{5-[4-(3,3-dimethyl-azetidine-1-carbonyl)-phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl}-amide;AS-56075;MFCD26960569;Cyclopropanecarboxamide, N-(5-(4-((3,3-dimethyl-1-azetidinyl)carbonyl)phenyl)(1,2,4)triazolo(1,5-a)pyridin-2-yl)-;SB16965;GTPL9697;EX-A2326;CHEMBL3301606;Q27258083;1206163-45-2;G-154578;AKOS025289798;Solcitinib [USAN];BDBM128101;BCP23893;GLPG-0778;Solcitinib;US8796457, 1;UNII-3V7GQ1260K;N-{5-[4-(3,3-dimethylazetidine-1-carbonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl}cyclopropanecarboxamide;SOLCITINIB [WHO-DD];N-(5-(4-((3,3-DIMETHYL-1-AZETIDINYL)CARBONYL)PHENYL)(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)CYCLOPROPANECARBOXAMIDE;GLPG-0788;cyclopropanecarboxylic acid {5-[4-(3,3-dimethyl-azetidine-1-carbonyl)-phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl}-amide;N-(5-(4-((3,3-dimethylazetidin-1-yl)carbonyl)phenyl)(1,2,4)triazolo(1,5-a)pyridin-2-yl)cyclopropanecarboxamide;CS-5204;D10728;SCHEMBL2240393;s5917;NCGC00484062-01;BRD-K69215269-001-01-1;Solcitinib (USAN/INN) |
微信公众号
客服
